cohort size, representation across sexes, and serology-based diagnostic capability for chronic hepatitis (B and C). Our findings of no statistically significant association between psoriasis and chronic hepatitis B and/or C in this large US population contribute to the limited existing literature to allow for a greater clarity of risk assessment, especially for that of viral reactivation. 
Smoking and risk of psoriasis: A nationwide cohort study To the Editor: Smoking is a health hazard and also a potential risk factor for psoriasis. 1, 2 Several studies previously showed an association between smoking and the severity of psoriasis. 2, 3 However, because of their small size, the results were inconclusive. We therefore examined the independent relationship between smoking status and psoriasis by performing a large-scale nationwide cohort study (institutional review board No. KC17EISE0012). We used the representative database of the Korean National Health Insurance from 2005 through 2015. A total of 17,055,608 subjects over the age of 20 years who underwent a health examination in 2005-2008 were followed for 8 years. The incidence ratio (IR) of psoriasis with a 95% confidence interval (CI) adjusted for age, sex, alcohol consumption, physical activity, body mass index, and comorbidities was estimated by Poisson regression. The hazard ratio (HR) was estimated by Cox regression analysis.
The reference group comprised individuals who had never smoked (Table I ). The IR ( per 1000) of psoriasis was 3.71 for former smokers and 3.54 for current smokers, respectively. In multivariate analyses, compared with nonsmokers, former smokers (adjusted IR, 1.11; 95% CI, 1.10-1.12) and current smokers (adjusted IR, 1.14; 95% CI, 1.13-1.15) had a significantly higher risk for development of psoriasis. These results indicate that smoking status is an independent potential risk factor for psoriasis. In addition, the risk for psoriasis was increased with amount and duration of smoking (P for trend \.0001) (Fig 1) . There was a statistically significant positive correlation between risk for psoriasis and total period of smoking (P for trend \.0001). Furthermore, the HR for psoriasis was lowest in individuals who had smoked fewer than 0.5 packs per day (HR, 1.11) and highest in individuals who smoked more than 2 packs per day (HR, 1.25). Psoriasis is a chronic inflammatory disease that is mediated by Th1 and Th17 helper T cells. Smoking produces free radicals that may activate signaling pathways implicated in psoriasis, such as the mitogen-activated kinase, nuclear factor B, and Janus kinase-STAT pathways. 4 Byproducts from smoking, such as nicotine and dioxin, activate T cells that produce interleukin 12 (IL-12), IL-17, and IL-22. 5 Because IL-17 is one of the major cytokines involved in the pathogenesis of psoriasis, there are mechanistic reasons to believe that smoking could contribute to development of psoriasis.
In a previous meta-analysis, psoriasis was associated with smoking history, with a pooled odds ratio of 1.62 (95% CI, 1.33-1.98). 2 The relationship between smoking and moderate to severe psoriasis had a pooled odds ratio of 1.72 (95% CI, 1.33-1.98). 2 In the present study, former smokers and current smokers were at increased risk for the development of psoriasis and the risk was still valid after adjustment for confounding factors. Our results are consistent with those of previous studies. Meanwhile, Armstrong et al did not fully report the association between psoriasis and the amount of cigarettes smoked. 2 The association between duration of smoking and psoriasis has been controversial. 2 In this study, we clearly showed that there is a positive correlation between the amount and/or duration of smoking and the occurrence of psoriasis. However, our study has a limitation in that any change in smoking status after registration has not been reflected. In addition, association does not demonstrate cause and effect; therefore, further investigation is needed. 2 D circulate bound to VD-binding protein (DBP) (85%-90%) and albumin (10%-15%), with \1% circulating in its free form. Low DBP levels have been described as a potential cancer risk biomarker, adding complexity to the VD axisecancer association. 2 Recent studies have shown a better correlation of bioavailable ( free plus albumin-bound) 25(OH)D than total 25(OH)D with measures of bone mineral metabolism. 3 Higher free 25(OH)D levels have also been associated with decreased risk for colorectal but not breast cancer. 3 To the best of our knowledge, no studies have evaluated DBP and free and bioavailable 25(OH)D levels in melanoma patients.
A case-control study was conducted prospectively. The scientific ethics committee of our institution approved this study. We included adult patients with a recent diagnosis of melanoma; blood samples were taken \3 weeks after diagnosis. Exclusion criteria were VD-supplement use during the previous 6 months, pregnancy, lactation, immunosuppression, bone metabolism alterations, granulomatous diseases, and concurrent cancer. The control group included healthy age-, sex-, season-and skintypeepaired patients without histories of dysplastic nevi or skin cancer and without other exclusion criteria reported for melanoma patients.
We measured serum 25(OH)D (by liquid chromatographyetandem mass spectrometry) and DBP (by polyclonal ELISA, AssayPro LLC, St. Charles, MO). 25(OH)D levels were categorized as deficient (\50 nmol/L), insufficient (50-74 nmol/L), or sufficient ($75 nmol/L) according to current Endocrine Society guidelines. 4 Free and bioavailable 25(OH)D were calculated as described. 5 We included 40 melanoma patients and 56 controls; clinical and laboratory characteristics are shown in Table I . DBP levels were significantly lower in melanoma patients than in controls (P \ .001). Upon comparing invasive melanoma, melanoma in situ, and controls, a significant trend of higher DBP levels corresponding with healthier populations was observed (P ¼ .002, Fig 1) . No
